Clinical TrialJul 7, 2026, 08:11 AM
Nanox.AI Cardiac AI Data Shows High Agreement at SCCT 2026
AI Summary
Nanox Imaging Ltd. announced that data from studies featuring its Nanox.AI cardiac solution (HealthCCSng) will be presented at the 21st Annual Scientific Meeting of the Society of Cardiovascular Computed Tomography (SCCT). New abstracts from Brigham and Women’s Hospital highlight the FDA-cleared solution's high agreement with expert assessment and its potential role in supporting guideline-directed preventive care. The AI INFORM trial also demonstrates how AI-detected coronary calcium can help clinicians identify opportunities for preventive lipid-lowering therapy. Nanox.AI is also sponsoring a scientific session at the event.
Key Highlights
- Nanox.AI's FDA-cleared cardiac AI solution (HealthCCSng) data presented at SCCT 2026.
- New abstracts highlight high agreement of HealthCCSng with expert assessment for coronary artery calcium.
- AI INFORM randomized trial shows AI-detected coronary calcium aids preventive lipid-lowering therapy.
- Studies presented by Brigham and Women’s Hospital, Massachusetts General Hospital, and other institutions.
- Nanox.AI sponsors a scientific session on Aortic Valve Calcification on Chest CT at SCCT.
Price Impact
More from NNOX